Printer Friendly

Mylan Inc reports availibility of generic Tricor Tablets, 48 mg and 145 mg.

M2 EQUITYBITES-May 20, 2013-Mylan Inc reports availibility of generic Tricor Tablets, 48 mg and 145 mg(C)2013 M2 COMMUNICATIONS

Pharmaceutical company Mylan Inc (NasdaqGS:MYL) reported on Friday the shipment of Fenofibrate Tablets, 48 mg and 145 mg, following the final approval from the US Food and Drug Administration (FDA).

This shipment has been initiated by the company's subsidiary, Mylan Pharmaceuticals Inc.

The company said that the Fenofibrate Tablets, 48 mg and 145 mg are the generic version of Abbvie Inc's Tricor Tablets.

Fenofibrate Tablets are reportedly indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), Triglycerides and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia.

According to IMS Health, Fenofibrate Tablets, 48 mg and 145 mg, had US sales of approximately USD1.2bn for the 12 months ending 31 March 2013.

((Comments on this story may be sent to

COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:May 20, 2013
Previous Article:Norden and Harris CapRock extend agreement to add VSAT Communications Services to Norden's global fleet.
Next Article:EnteroMedics Inc concludes its obesity VBLOC therapy Pre-PMA Meeting with the US FDA.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters